HMP CommunicationsCosibelimab Safe, Clinically Active in Patients With mCSCC

In Study CK-301-101, the primary efficacy endpoint was objective response rate (complete + partial response, by independent central review), which was 47% (n = 15) in 32 mCSCC patients evaluable for response, including 3 complete responses and 12 partial responses. The results from the study were presented at the ESMO Congress.